Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FOLD @ Stockcharts
Looks like bottoms up..took starter position $2.30
http://finance.yahoo.com/news/amicus-therapeutics-provides-full-2014-123000037.html -FABRY in JUNE-
Bought back in $8.50
Investor 100
Amicus Therapeutics Provides Full-Year 2014 Strategic Outlook and Financial Guidance
http://finance.yahoo.com/news/amicus-therapeutics-provides-full-2014-123000037.html
Amicus Therapeutics (FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease
CORT @ Stockcharts
A beastly run in 2014!
Pipeline Progress at Corcept
http://finance.yahoo.com/news/pipeline-progress-corcept-210502627.html
We remind investors that Corcept enjoys orphan drug designation for Korlym from the U.S. Food and Drug Administration (:FDA) for the approved indication.
BONE @Stockcharts
Inching closer to the 200MA!
http://finance.yahoo.com/q/mh?s=BONE+Major+Holders
FOLD @ Stockcharts
Ready for the next leg up to the 200MA.
http://seekingalpha.com/article/1856211-amicus-therapeutics-ceo-hosts-strategic-update-conference-transcript?page=6
SEC Filings @ FOLD
http://finance.yahoo.com/q/sec?s=FOLD+SEC+Filings
Research Reports:
http://finance.yahoo.com/q/rr?s=FOLD+Research+Reports
Insider Roster:
http://finance.yahoo.com/q/ir?s=FOLD+Insider+Roster
Major Holders:
http://finance.yahoo.com/q/mh?s=FOLD+Major+Holders
Investor 100
IBIO @ Stockcharts
Solid 19% gainer passing the 200MA and MFI moving upward..follow the money..watch-list!
Pipeline:http://ibioinc.com/products/
RNN @ Stockcharts
Solid MOMO run on this stock up 62% out the gates for 2014!
http://finance.yahoo.com/news/rexahn-initiates-phase-ib-clinical-130000785.html
Outstanding performance yesterday- on my watch-list!
Investor 100
Too profit from a $3.80 entry out at $8.80 yesterday!
Look to re-enter.
Investor 100
CRMD @ Stockcharts
Solid MOMO movement today...+14% with today's news!
New management team in 2012 appears to be moving in the right direction....watch-list!
http://seekingalpha.com/article/1923361-cormedix-an-interesting-play-in-the-catheter-care-space
CorMedix Awarded European Patent for Neutrolin
http://finance.yahoo.com/news/cormedix-awarded-european-patent-neutrolin-133200896.html
MSTX @ Stockcharts
Wow..took off on positive news blowing pass the 200MA..2014 looks like an interesting play!
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
- Statistically significant improvement in key parameters of heart function, including left ventricular ejection fraction and cardiac output
http://finance.yahoo.com/news/mast-therapeutics-announces-positive-data-130000374.html
NVLX @ Stockcharts
Bottoms up with the MFI turning up and the crossing of the 200/50..high risk /reward for pancreatic cancer along with medical marijuana..have a position.
Nuvilex's Provides Progress Update on Cell Cloning Being Performed by Inno Biologics
Cloning Essential to Obtain Cells for Future Late Phase Clinical Trials in Pancreatic Cancer
http://finance.yahoo.com/news/nuvilexs-provides-progress-cell-cloning-143000067.html
http://finance.yahoo.com/news/nuvilexs-medical-marijuana-research-could-140000739.html ( medical marijuana possibilities)
DARA @ Stockcharts
Stock blasting out the doors in 2014 with much anticipation...MFI turning back up and the 200MA around the corner...some nice designations "Fast Track Drug and and seeking "Orphan Status" all good news...watching closely for a position.
http://finance.yahoo.com/news/dara-biosciences-completes-breast-cancer-133000249.html
DARA is focused on expanding its portfolio of oncology supportive care products in the United States, via in-licensing and/or partnering of complementary late-stage and approved products. In addition, the company wishes to identify a strategic partner for the clinical development of KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy-induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track Drug, and DARA is seeking orphan status for the treatment of CCIPN.
In 2014, DARA kicks off its new partnership with Alamo Pharma Services, a subsidiary of Mission Pharmacal, in deploying a dedicated 20-person national sales team in the U.S. oncology market. In addition to promoting DARA's products Soltamox® (tamoxifen citrate), Gelclair® and Bionect®, this specialized oncology supportive care sales team also will provide clinicians with access to three Mission Pharmacal products: Ferralet® 90 (for anemia), BINOSTO® (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral® (for chemotherapy/radiation therapy-induced dry mouth).
DARA: Building An Oncology And Supportive Care Specialty Pharma
http://finance.yahoo.com/news/dara-building-oncology-supportive-care-120000065.html
NBS @ Stockcharts
Solid MOMO movement with a 4% gainer...MFI moving upward..follow the $$$ and into the 3rd quarter of 2014- watch-list!
NeoStem Completes Patient Enrollment in Phase 2 AMR-001 Trial for Prevention of Adverse Cardiovascular Events Following a Heart Attack
PreSERVE AMI Data Readout Expected in Third Quarter 2014
http://finance.yahoo.com/news/neostem-completes-patient-enrollment-phase-123000348.html
Horizon Pharma's CEO Discusses Q3 2013 Results - Earnings Call Transcript ( November 8th,2013)
http://seekingalpha.com/article/1823202-horizon-pharmas-ceo-discusses-q3-2013-results-earnings-call-transcript
Some Highlights:
We delivered third quarter total net sales of $26.2 million, an increase of a 114% versus the second quarter of 2013. We also exited the quarter with approximately $58.7 million in cash and cash equivalent versus $69.3 million at the end of the second quarter. In the third quarter DUEXIS continued to demonstrate momentum with total prescriptions increasing approximately 18% versus the second quarter of 2013 and total net sales of DUEXIS is $23.5 million, an increase of a 122% versus the second quarter of 2013 with current annual net sales at a run rate of greater than $94 million.
So to-date, almost 20,000 physicians have written prescriptions for DUEXIS, with the majority of scripts being written by primary care physicians, followed by orthopedic surgeons and rheumatologists. We are pleased with the continued productivity of our sales force as measured on our prescriptions per representative basis. Additionally, we have seen from Q2 to Q3 an average increase of 14%, the number of writers on a weekly basis.
Turning to RAYOS, net sales in the third quarter were $2 million an increase of over 250% versus the second quarter of 2013. We are encouraged by the feedback and growing acceptance of RAYOS by both rheumatologists and patients. We recently presented data at the America College of Rheumatology meeting that patients of arthritis treated with the RAYOS at bed time had significant and sustained improvement in the morning symptoms for the one-year duration study as compared to group of patients treated with immediate release Premizone given in the waking hours.
IDRA @ Stockcharts
Nice MOMO run and going strong with compelling storyline- watch-list!
Idera Pharmaceuticals Presents a Promising Opportunity
http://wallstcheatsheet.com/stocks/idera-pharmaceuticals-presents-a-promising-opportunity.html/?ref=YF
http://finance.yahoo.com/news/idera-pharmaceuticals-opens-enrollment-phase-123000547.html
Idera previously announced that it intends to submit a protocol to the FDA to conduct a Phase 1/2 trial in patients with diffuse large B-cell lymphoma (DLBCL) in the first quarter of 2014. DLBCL is an aggressive lymphoma. Approximately 30% of the patients with the activated B-cell-like, or ABC, sub-type are reported to also have MYD88 L265P mutation.
Form 4: Inside buys ( vote of confidence)
http://openinsider.com/search?q=idra
Institutional Holdings @ SGYP
Breakdown
% of Shares Held by All Insider and 5% Owners: 8%
% of Shares Held by Institutional & Mutual Fund Owners: 17%
% of Float Held by Institutional & Mutual Fund Owners: 19%
Number of Institutions Holding Shares: 67
Major Direct Holders (Forms 3 & 4)
Holder Shares Reported
HUNTER ROBERT MERRILL 7,243,557 Jan 17, 2013
CERRONE GABRIEL N/A Oct 29, 2013
JACOB GARY S 314,786 Jan 17, 2013
BRANCACCIO JOHN P 20,444 Jan 17, 2013
DENOYER BERNARD 7,500 Jun 21, 2013
Top Institutional Holders
Holder Shares % Out Value* Reported
Vanguard Group, Inc. (The) 4,094,747 4.54 18,712,993 Sep 30, 2013
FMR, LLC 3,453,656 3.83 15,783,207 Sep 30, 2013
BlackRock Fund Advisors 3,254,456 3.61 14,872,863 Sep 30, 2013
Baker Brothers Advisors, LLC 2,608,271 2.89 11,919,798 Sep 30, 2013
State Street Corporation 1,236,933 1.37 5,652,783 Sep 30, 2013
Northern Trust Corporation 1,095,163 1.21 5,004,894 Sep 30, 2013
BlackRock Institutional Trust Company, N.A. 1,074,550 1.19 4,910,693 Sep 30, 2013
Wall Street Associates 942,200 1.04 4,305,854 Sep 30, 2013
Morgan Stanley 877,819 0.97 4,011,632 Sep 30, 2013
UBS Global Asset Management (Americas) Inc 624,700 0.69 2,854,879 Sep 30, 2013
Top Mutual Fund Holders
Holder Shares % Out Value* Reported
Fidelity Select Portfolios - Biotechnology 2,411,172 2.67 9,741,134 Oct 31, 2013
iShares Russell 2000 Index Fund 1,394,249 1.55 5,632,765 Oct 31, 2013
Vanguard Small-Cap Index Fund 1,300,343 1.44 5,942,567 Sep 30, 2013
Vanguard Total Stock Market Index Fund 1,137,242 1.26 5,197,195 Sep 30, 2013
iShares NASDAQ Biotechnology Index Fund 983,766 1.09 3,974,414 Oct 31, 2013
Vanguard Small Cap Value Index Fund 670,384 0.74 3,063,654 Sep 30, 2013
Vanguard Extended Market Index Fund 648,895 0.72 2,965,450 Sep 30, 2013
iShares Russell 2000 Growth Index Fund 612,007 0.68 2,472,508 Oct 31, 2013
Fidelity Small Cap Growth Fund 381,824 0.42 1,542,568 Oct 31, 2013
College Retirement Equities Fund-Stock Account 319,809 0.35 1,461,527 Sep 30, 2013
http://finance.yahoo.com/q/mh;_ylt=A0oG7lbId8dS5QUADkFXNyoA;_ylu=X3oDMTEzcDVzdjNvBHNlYwNzcgRwb3MDNQRjb2xvA2FjMgR2dGlkA1ZJUDM0OF8x?s=SGYP+Major+Holders
FOLD @ Stockcharts
Steady climb upward gaining on the 200MA!
Amicus Therapeutics Raises Funds ( Good til 2015)
http://finance.yahoo.com/news/amicus-therapeutics-raises-funds-205504996.html
http://www.minyanville.com/trading-and-investing/stocks/articles/GlaxoSmithKline-Noted-Biotech-Investor-Randall-Kirk/11/25/2013/id/52832?camp=syndication&medium=portals&from=yahoo
BIOD @ Stockcharts
Nice MOMO with a 8% gainer heading for the 200MA!
Biodel Offers Opportunity in the Growing Insulin, Glucagon Markets
http://www.thestreet.com/story/12180251/1/biodel-offers-opportunity-in-the-growing-insulin-glucagon-markets.html?puc=yahoo&cm_ven=YAHOO
A Risk-Reward play...looks interesting indeed!
http://seekingalpha.com/article/1925191-biodel-inc-strong-biotech-january-effect-candidate-for-2014?source=yahoo
SGYP @ Stockckarts
Solid upward movement- on watch-list!
Synergy Pharma Progresses with Plecanatide
http://finance.yahoo.com/news/synergy-pharma-progresses-plecanatide-213004230.html
Form 4: Plenty of insiders buying- vote of confidence!
http://openinsider.com/search?q=sgyp
http://seekingalpha.com/article/1911851-these-small-cap-biopharma-companies-have-catalysts-upcoming?source=yahoo
NVLX @ Stockcharts
Nice movement and 2014 should be interesting indeed with MFI turning up...took a starter position.
Nuvilex's Medical Marijuana Subsidiary Poised for Growth in the New Year
http://finance.yahoo.com/news/nuvilexs-medical-marijuana-subsidiary-poised-143000176.html
Voters in both Colorado and Washington approved recreational marijuana in 2012, but Colorado was quick to implement the laws allowing approved marijuana businesses to open on New Year's Day. Washington state's recreational marijuana shops are expected to open later in the year. Uruguay recently became the first country in the world to create a legal, regulated marijuana market for adults.
http://www.huffingtonpost.com/2014/01/01/marijuana-shops-open-colorado_n_4519506.html
DARA @ Stockcharts
Nice movement forward with 3% gainer..2M shares and MFI turning up and 200MA..follow the $$!
Nice catalyst coming up too:)
ARA is focused on expanding its portfolio of oncology supportive care products in the United States, via in-licensing and/or partnering of complementary late-stage and approved products. In addition, the company wishes to identify a strategic partner for the clinical development of KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy-induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track Drug, and DARA is seeking orphan status for the treatment of CCIPN.
SNGX @ Stockcharts
Nice movement today with a 10.5% gainer with MFI making its turn upward!
SGX942 has received fast track designation from the US Food and Drug Administration (FDA) for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-threatening condition and one that demonstrates the potential to address an unmet medical need for the condition. Fast track designation is designed to facilitate the development and expedite the review of new drugs. For instance, should events warrant, Soligenix will be eligible to submit a new drug application (NDA) for SGX942 on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving the complete submission. Additionally, NDAs for fast track development programs ordinarily will be eligible for priority review, which imparts an abbreviated review time of approximately six months.
http://finance.yahoo.com/news/soligenix-announces-initiation-phase-2-121500296.html
NVLX @ Stockcharts
Nice movement today with a 12.5% gainer.. on my watch-list!
http://finance.yahoo.com/news/dr-mark-l-rabe-develops-143000346.html
ECTE @ Stockcharts
Blasting out the doors for 2014- 11%+ gainer and going after the 200MA!
http://finance.yahoo.com/news/ectes-glucose-monitoring-device-enters-190005258.html ( China is a huge market)!
CVM @ Stockcharts
Out the gates for 2014 with a 9%+ gainer and going after the 50MA!
http://finance.yahoo.com/news/cel-sci-reports-fiscal-2013-153300984.html
CEL-SCI Reports Fiscal 2013 Financial Results and Clinical & Corporate Developments